Torcetrapib and coronary events.

Suppr

超能文献

作者信息

Cohn Lawrence J

出版信息

N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.

PMID:18437724

Abstract

摘要

相似文献

Torcetrapib and coronary events.

N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.

The failure of torcetrapib: was it the molecule or the mechanism?

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.

Effects of torcetrapib in patients at high risk for coronary events.

N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5.

Effect of torcetrapib on the progression of coronary atherosclerosis.

N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26.

High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.

Cardiovasc Res. 2008 Mar 1;77(4):614-5. doi: 10.1093/cvr/cvn003. Epub 2008 Jan 10.

Torcetrapib and coronary events.

N Engl J Med. 2008 Apr 24;358(17):1862-3; author reply 1863-4. doi: 10.1056/NEJMc073441.

CETP inhibitors to increase HDL cholesterol levels.

N Engl J Med. 2007 Mar 29;356(13):1364-6. doi: 10.1056/NEJMe078029. Epub 2007 Mar 26.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

N Engl J Med. 2007 Apr 19;356(16):1620-30. doi: 10.1056/NEJMoa071359. Epub 2007 Mar 26.

Development of torcetrapib, a lipid-lowering drug, abandoned.

Prescrire Int. 2007 Jun;16(89):114.

Cholesteryl ester transfer protein antagonism by drugs--a poor choice.

Clin Chem. 2010 Oct;56(10):1550-3. doi: 10.1373/clinchem.2010.147389. Epub 2010 Aug 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Torcetrapib and coronary events.

N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.

The failure of torcetrapib: was it the molecule or the mechanism?

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.

Effects of torcetrapib in patients at high risk for coronary events.

N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5.

Effect of torcetrapib on the progression of coronary atherosclerosis.

N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26.

High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.

Cardiovasc Res. 2008 Mar 1;77(4):614-5. doi: 10.1093/cvr/cvn003. Epub 2008 Jan 10.

Torcetrapib and coronary events.

N Engl J Med. 2008 Apr 24;358(17):1862-3; author reply 1863-4. doi: 10.1056/NEJMc073441.

CETP inhibitors to increase HDL cholesterol levels.

N Engl J Med. 2007 Mar 29;356(13):1364-6. doi: 10.1056/NEJMe078029. Epub 2007 Mar 26.

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

N Engl J Med. 2007 Apr 19;356(16):1620-30. doi: 10.1056/NEJMoa071359. Epub 2007 Mar 26.

Development of torcetrapib, a lipid-lowering drug, abandoned.

Prescrire Int. 2007 Jun;16(89):114.

Cholesteryl ester transfer protein antagonism by drugs--a poor choice.

Clin Chem. 2010 Oct;56(10):1550-3. doi: 10.1373/clinchem.2010.147389. Epub 2010 Aug 27.